File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis

TitlePharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis
Authors
Keywords3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor
Cirrhosis
Liver
Pharmacokinetics
Pitavastatin
Statin
Issue Date2005
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCP
Citation
British Journal Of Clinical Pharmacology, 2005, v. 59 n. 3, p. 291-297 How to Cite?
AbstractAim: Lipid lowering therapy with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors is increasingly used for the prevention of cardiovascular events, but they should be used with caution in patients with impaired liver function. We therefore studied the pharmacokinetics of pitavastatin in patients with liver cirrhosis. Methods: Plasma concentrations of pitavastatin were determined after administration of 2 mg single-dose pitavastatin to 12 male patients with liver cirrhosis (six Child-Pugh grade A and six grade B). These results were compared with the single-dose pharmacokinetic results obtained from six male volunteers without liver disease. Results: Administration of 2 mg single-dose pitavastatin to patients with Child-Pugh grade A and grade B cirrhosis resulted in a 1.19- and 2.47-fold increase in Cmax and 1.27-and 3.64-fold increase in AUCt, respectively, when compared with normal subjects. The geomean Cmax of pitavastatin was 59.5 ng ml-1, 70.7 ng ml-1 and 147.1 ng ml-1 in the control, Child-Pugh grade A and Child-Pugh grade B groups, respectively. The geomean AUCt of pitavastatin in the three groups was 121.2 ng h-1 ml-1, 154.2 ng h-1 ml-1 and 441.7 ng h-1 ml-1, respectively. The geomean Cmax of pitavastatin lactone was 20.3 ng ml-1, 19.1 ng ml-1 and 9.9 ng ml-1 in the control, Child-Pugh grade A and grade B groups, respectively. The AUCt of pitavastatin lactone was 120.2 h-1 ml-1, 108.8 h-1 ml -1 and 87.5 h-1 ml-1, respectively. Conclusion: The plasma concentration of pitavastatin is increased in patients with liver cirrhosis. In such patients, caution is required, although dose reduction may not be necessary in Child-Pugh A cirrhosis. © 2004 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/49049
ISSN
2015 Impact Factor: 3.83
2015 SCImago Journal Rankings: 1.486
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHui, CKen_HK
dc.contributor.authorCheung, BMYen_HK
dc.contributor.authorLau, GKKen_HK
dc.date.accessioned2008-06-12T06:33:19Z-
dc.date.available2008-06-12T06:33:19Z-
dc.date.issued2005en_HK
dc.identifier.citationBritish Journal Of Clinical Pharmacology, 2005, v. 59 n. 3, p. 291-297en_HK
dc.identifier.issn0306-5251en_HK
dc.identifier.urihttp://hdl.handle.net/10722/49049-
dc.description.abstractAim: Lipid lowering therapy with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors is increasingly used for the prevention of cardiovascular events, but they should be used with caution in patients with impaired liver function. We therefore studied the pharmacokinetics of pitavastatin in patients with liver cirrhosis. Methods: Plasma concentrations of pitavastatin were determined after administration of 2 mg single-dose pitavastatin to 12 male patients with liver cirrhosis (six Child-Pugh grade A and six grade B). These results were compared with the single-dose pharmacokinetic results obtained from six male volunteers without liver disease. Results: Administration of 2 mg single-dose pitavastatin to patients with Child-Pugh grade A and grade B cirrhosis resulted in a 1.19- and 2.47-fold increase in Cmax and 1.27-and 3.64-fold increase in AUCt, respectively, when compared with normal subjects. The geomean Cmax of pitavastatin was 59.5 ng ml-1, 70.7 ng ml-1 and 147.1 ng ml-1 in the control, Child-Pugh grade A and Child-Pugh grade B groups, respectively. The geomean AUCt of pitavastatin in the three groups was 121.2 ng h-1 ml-1, 154.2 ng h-1 ml-1 and 441.7 ng h-1 ml-1, respectively. The geomean Cmax of pitavastatin lactone was 20.3 ng ml-1, 19.1 ng ml-1 and 9.9 ng ml-1 in the control, Child-Pugh grade A and grade B groups, respectively. The AUCt of pitavastatin lactone was 120.2 h-1 ml-1, 108.8 h-1 ml -1 and 87.5 h-1 ml-1, respectively. Conclusion: The plasma concentration of pitavastatin is increased in patients with liver cirrhosis. In such patients, caution is required, although dose reduction may not be necessary in Child-Pugh A cirrhosis. © 2004 Blackwell Publishing Ltd.en_HK
dc.format.extent388 bytes-
dc.format.mimetypetext/html-
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCPen_HK
dc.relation.ispartofBritish Journal of Clinical Pharmacologyen_HK
dc.rightsBritish Journal of Clinical Pharmacology. Copyright © Blackwell Publishing Ltd.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsThe definitive version is available at www.blackwell-synergy.comen_HK
dc.subject3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitoren_HK
dc.subjectCirrhosisen_HK
dc.subjectLiveren_HK
dc.subjectPharmacokineticsen_HK
dc.subjectPitavastatinen_HK
dc.subjectStatinen_HK
dc.titlePharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosisen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0306-5251&volume=59&issue=3&spage=291&epage=297&date=2005&atitle=Pharmacokinetics+of+pitavastatin+in+subjects+with+Child-Pugh+A+and+B+cirrhosisen_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1111/j.1365-2125.2004.02251.xen_HK
dc.identifier.pmid15752374en_HK
dc.identifier.pmcidPMC1884781en_HK
dc.identifier.scopuseid_2-s2.0-15244362340en_HK
dc.identifier.hkuros120020-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-15244362340&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume59en_HK
dc.identifier.issue3en_HK
dc.identifier.spage291en_HK
dc.identifier.epage297en_HK
dc.identifier.isiWOS:000227387400005-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridHui, CK=7202876933en_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats